ProMIS Neurosciences Inc.
PMN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$9.68
KIRA · Stoqly’s AI analyst, in plain words
- ProMIS Neurosciences Inc. lost $39.7M in fiscal 2025.
Market cap
$88.5M
P/E
—
Revenue
—
Net income
−$39.7M
Free cash flow
—
Operating margin
—
ProMIS Neurosciences Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$39.7M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ProMIS Neurosciences Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- ProMIS Neurosciences Inc.
- CIK
- 0001374339
ProMIS Neurosciences Inc. · PMN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$9.8M | −$18.1M | −$13.2M | $2.8M | −$39.7M |
| Diluted EPS | −$1.69 | −$2.41 | −$1.07 | $2.63 | −$22.61 |
| Cash | |||||
| Cash from operations | −$9.3M | −$17.0M | −$10.8M | −$27.2M | −$28.1M |
| Capital expenditure | $0.0M | $0.0M | — | — | — |
| Free cash flow | −$9.3M | −$17.0M | — | — | — |
| Share count change | — | 29.7% | 63.8% | −91.4% | 66.0% |
| Debt and strength | |||||
| Cash and short-term investments | $17.0M | $5.9M | $12.6M | $13.3M | $6.2M |
| Debt incl. finance leases | $3.9M | — | $0.0M | — | — |
| Shareholders' equity | $5.7M | −$1.3M | $3.8M | $16.5M | −$1.3M |
| Current ratio | 19.1x | 1.1x | 1.5x | 8.5x | 0.9x |
| Interest coverage | −19.9x | −82.9x | — | — | — |
| Returns and quality | |||||
| Return on equity | −173.0% | −837.7% | −1,098.5% | 27.5% | −521.6% |
| Return on tangible equity | 173.8% | — | −352.0% | 16.9% | — |
| Altman Z'' | −7.9 | −60.2 | −27.0 | −8.7 | −76.7 |
Insiders bought, 12 months
$8.7M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ProMIS Neurosciences Inc. · PMN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.68 a share, the company is worth $88.5M.
Source: SEC EDGAR XBRL filings (CIK 0001374339). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.